Disease · MONDO_0006362

peritoneal mesothelioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. peritoneal mesothelioma. Diseases, record MONDO_0006362. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006362

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: peritoneal mesothelioma; Open Targets
Open Targets ID: MONDO_0006362; Open Targets
Other names: mesothelioma of peritoneum, mesothelioma of the peritoneum, peritoneal mesothelioma (disease), peritoneum mesothelioma; Open Targets
NCI Thesaurus: C7633; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 1 of its 20 drugs, from ClinicalTrials.gov; Open Targets

Drugs20

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
PEMETREXED	CHEMBL225072	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOMVANALIMAB	CHEMBL4650392	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOXORUBICIN HYDROCHLORIDE	CHEMBL359744	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
GEMCITABINE HYDROCHLORIDE	CHEMBL1637	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 20

See all 20 drugs

Targets40

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	2	Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
TYMS	Thymidylate synthase	2	Thymidylate synthase inhibitor	Phase 2	https://conductscience.org/library/genes/7298	Drugs and targets
CD274	Programmed cell death 1 ligand 1	1	Programmed cell death 1 ligand 1 inhibitor	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Phase 2	https://conductscience.org/library/genes/1719	Drugs and targets
GART	Trifunctional purine biosynthetic protein adenosine-3	1	GAR transformylase inhibitor	Phase 2	https://conductscience.org/library/genes/2618	Drugs and targets
IFNGR1	Interferon gamma receptor	1	Interferon gamma receptor agonist	Phase 2	https://conductscience.org/library/genes/3459	Drugs and targets
IFNGR2	Interferon gamma receptor	1	Interferon gamma receptor agonist	Phase 2	https://conductscience.org/library/genes/3460	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/23649	Drugs and targets

1 to 10 of 40

See all 40 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00004547	Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy	Phase 2	188	2011-11-22	Abdominal Neoplasm, Colonic Neoplasm, Mesothelioma, Peritoneal Neoplasm	CISPLATIN, FLUOROURACIL, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT02834013	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Phase 2	798		Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma	IPILIMUMAB, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT03063450	CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma	Phase 3	332		Mesothelioma	NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02029690	Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin	Phase 1	85		Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma, Hepatocellular Carcinoma, Glioma, Sarcomatoid Carcinoma	CISPLATIN, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT05001880	Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma	Phase 2	66		Peritoneal Malignant Mesothelioma	ATEZOLIZUMAB, BEVACIZUMAB, CARBOPLATIN, PEMETREXED	Its record names the disease	ClinicalTrials.gov
NCT07510815	Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma	Phase 1/2	36		Malignant Pleural Mesotheliomas	CYCLOPHOSPHAMIDE, FLUDARABINE	Its record names the disease	ClinicalTrials.gov
NCT00003046	Interleukin-12 in Treating Patients With Cancer in the Abdomen	Phase 1	29		Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer	INTERLEUKIN-12 HUMAN RECOMBINANT	Its record names the disease	ClinicalTrials.gov
NCT06790706	IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers	Phase 2	27		Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor, Carcinoid Tumor, Thymic Carcinoma	DOMVANALIMAB, ZIMBERELIMAB	Its record names the disease	ClinicalTrials.gov
NCT01443260	A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis	Phase 1/2	9		Peritoneal Carcinomatosis	OLVIMULOGENE NANIVACIREPVEC	Its record names the disease	ClinicalTrials.gov
NCT00024271	Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer	Phase 2			Malignant Mesothelioma	CISPLATIN, DOXORUBICIN HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE, MITOMYCIN	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials25

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
29669604	RESULT	1	PubMed
42499790	DERIVED	1	PubMed
41995270	DERIVED	1	PubMed
41892875	DERIVED	1	PubMed
41672597	DERIVED	1	PubMed
40588371	DERIVED	1	PubMed
40402690	DERIVED	1	PubMed
39856213	DERIVED	1	PubMed
39583952	DERIVED	1	PubMed
39417692	DERIVED	1	PubMed

1 to 10 of 25

See all 25 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006362

GET https://conductscience.org/api/diseases/v1/MONDO_0006362/targets?page=2

API reference For AI assistants